Austria-based Themis Bioscience, backed by a consortium of VC investors, is set to list on Euronext Amsterdam on 9 November with an indicative offering price of €9.70-11.60 per share.
Sale of the drive technology unit saw interest from sponsors including CVC, Triton and Brookfield
AUM bump driven by commitments to CapMan Nordic Real Estate III and CapMan Growth II funds
This round is an extension to an €11m series-B investment raised by the company in July 2019
Elevat3 Capital and German energy group EWE also back the green project-financing platform